Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 28;22(9):4687.
doi: 10.3390/ijms22094687.

Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer

Alessia Vignoli  1   2 , Emanuela Risi  3 , Amelia McCartney  3   4 , Ilenia Migliaccio  3 , Erica Moretti  3 , Luca Malorni  3 , Claudio Luchinat  1   2   5 , Laura Biganzoli  3 , Leonardo Tenori  1   2   5
Affiliations
Review

Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer

Alessia Vignoli et al. Int J Mol Sci. .

Abstract

Precision oncology is an emerging approach in cancer care. It aims at selecting the optimal therapy for the right patient by considering each patient's unique disease and individual health status. In the last years, it has become evident that breast cancer is an extremely heterogeneous disease, and therefore, patients need to be appropriately stratified to maximize survival and quality of life. Gene-expression tools have already positively assisted clinical decision making by estimating the risk of recurrence and the potential benefit from adjuvant chemotherapy. However, these approaches need refinement to further reduce the proportion of patients potentially exposed to unnecessary chemotherapy. Nuclear magnetic resonance (NMR) metabolomics has demonstrated to be an optimal approach for cancer research and has provided significant results in BC, in particular for prognostic and stratification purposes. In this review, we give an update on the status of NMR-based metabolomic studies for the biochemical characterization and stratification of breast cancer patients using different biospecimens (breast tissue, blood serum/plasma, and urine).

Keywords: NMR; breast cancer; chemotherapy; metabolomics; precision medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Precision oncology in a nutshell.
Figure 2
Figure 2
Selection of the scientific articles included in this NMR-based metabolomics review. The figure shows the workflow of the papers’ selection.
See this image and copyright information in PMC

References

    1. Lerner H.J., Band P.R., Israel L., Leung B.S. Phase II Study of Tamoxifen: Report of 74 Patients with Stage IV Breast Cancer. Cancer Treat. Rep. 1976;60:1431–1435. - PubMed
    1. Wiggans R.G., Woolley P.V., Smythe T., Hoth D., Macdonald J.S., Green L., Schein P.S. Phase-II Trial of Tamoxifen in Advanced Breat Cancer. Cancer Chemother. Pharm. 1979;3:45–48. doi: 10.1007/BF00254419. - DOI - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomised Trials. Lancet. 2005;365:1687–1717. doi: 10.1016/S0140-6736(05)66544-0. - DOI - PubMed
    1. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N. Engl. J. Med. 2011;365:1273–1283. doi: 10.1056/NEJMoa0910383. - DOI - PMC - PubMed
    1. Von Minckwitz G., Procter M., de Azambuja E., Zardavas D., Benyunes M., Viale G., Suter T., Arahmani A., Rouchet N., Clark E., et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N. Engl. J. Med. 2017;377:122–131. doi: 10.1056/NEJMoa1703643. - DOI - PMC - PubMed

LinkOut - more resources